<SEC-DOCUMENT>0001213900-20-022322.txt : 20200814
<SEC-HEADER>0001213900-20-022322.hdr.sgml : 20200814
<ACCEPTANCE-DATETIME>20200814170557
ACCESSION NUMBER:		0001213900-20-022322
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200810
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200814
DATE AS OF CHANGE:		20200814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		201106446

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea125571-8k_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): August 10, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-36374</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction<BR>
of incorporation)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer<BR>
Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>275 Madison Avenue, 7<SUP>th</SUP>
Floor, New York, NY 10016</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of Principal Executive Offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number:
(646) 677-3870</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<U>see</U>&nbsp;General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock, par value $0.001 per share</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>ATNM</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>NYSE American</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right; text-indent: 0.5in">Emerging growth
company&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.03 Amendment to Articles of Incorporation or Bylaws;
Change in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed,
on December 18, 2019, Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) held its annual meeting of its stockholders (the
&ldquo;Annual Meeting&rdquo;). At the Annual Meeting, the stockholders approved the proposal to authorize the board of directors
(the &ldquo;Board&rdquo;), in its discretion, to amend the Company&rsquo;s Certificate of Incorporation (the &ldquo;Certificate
of Incorporation&rdquo;) to effect a reverse stock split of the Company&rsquo;s common stock at a ratio not greater than 1-for-75,
such ratio to be determined by the Board before December 18, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 10, 2020,
the Board approved a 1-for-30 reverse stock split of the Company&rsquo;s issued and outstanding shares of common stock (the &ldquo;Reverse
Stock Split&rdquo;), and on August 10, 2020, the Company filed with the Secretary of State of the State of Delaware a Certificate
of Amendment to its Certificate of Incorporation (the &ldquo;Certificate Amendment&rdquo;) to effect the Reverse Stock Split, which
became effective as of 5:00 p.m. Eastern Time on August 10, 2020 (the &ldquo;Effective Time&rdquo;). The Company&rsquo;s common
stock began trading on a split-adjusted basis when the market opened on August 11, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Effective Time,
every 30 shares of the Company&rsquo;s issued and outstanding common stock automatically converted into one share of common stock,
without any change in the par value per share. As of the Effective Time, the Company adjusted and proportionately decreased the
number of shares of its common stock reserved for issuance upon exercise of, and adjusted and proportionately increased the exercise
price of, all options and warrants and other rights to acquire the Company&rsquo;s common stock. In addition, as of the Effective
Time, the Company adjusted and proportionately decreased the total number of shares of its common stock that may be the subject
of the future grants under the Company&rsquo;s stock plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will not
issue fractional shares in connection with the Reverse Stock Split. Instead, a stockholder who otherwise would be entitled to receive
fractional shares because it holds a number of shares not evenly divisible by the Reverse Stock Split ratio is entitled, upon surrender
to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction
to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock, as reported on the NYSE
American, on the last trading day prior to the Effective Time. The ownership of a fractional interest will not give the holder
thereof any voting, dividend or other rights except to receive payment therefor as described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
common stock will continue to trade on the NYSE American under the symbol &ldquo;ATNM.&rdquo; The new CUSIP number for common stock
following the Reverse Stock Split is 00507W206.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Action Stock Transfer
Corp, the Company&rsquo;s transfer agent, will act as the exchange agent for the Reverse Stock Split and Continental Stock Transfer
&amp; Trust Company will act as the paying agent for processing the cash payment in lieu of the fractional shares resulting from
the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information
about the Reverse Stock Split, see the Company&rsquo;s definitive proxy statement filed with the Securities and Exchange Commission
on November 25, 2019, the relevant portions of which are incorporated herein by reference. A copy of the Certificate Amendment
is attached as Exhibit 3.1 hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 10, 2020,
the Company announced that the Board approved a one-for-thirty reverse stock split of its common stock that is scheduled to become
effective after trading closes on August 10, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press
release announcing these events is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea125571ex3-1_actinium.htm">Certificate of Amendment to the Certificate of Incorporation of Actinium Pharmaceuticals, Inc.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea125571ex99-1_actinium.htm">Press release dated August 10, 2020</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><B>Actinium Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: &nbsp;August 14, 2020</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><I>/s/ Sandesh Seth</I></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ea125571ex3-1_actinium.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACTINIUM PHARMACEUTICALS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the
&ldquo;<U>Corporation</U>&rdquo;), does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. The
name of the corporation is Actinium Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Effective
as of 5:00 p.m., Eastern Time, on August 10, 2020 (the &ldquo;<U>Effective Time</U>&rdquo;), each thirty (30) issued and outstanding
shares of the Corporation&rsquo;s Common Stock, par value $0.001 per share, shall be converted into one (1) share of the Corporation&rsquo;s
Common Stock, par value $0.001 per share, as constituted following the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Subsection
(a) of Article Fourth of the Certificate of Incorporation of the Corporation (the &ldquo;<U>Certificate</U>&rdquo;) is hereby
restated in its entirety as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(a)
Common Stock. The aggregate number of shares of Common Stock which the Corporation shall have authority to issue is 1,000,000,000
shares at a par value of $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent
and effective upon the filing of this Certificate of Amendment to the Restated Certificate of Incorporation (the &ldquo;Certificate
of Amendment&rdquo;), each thirty (30) shares of the Corporation&rsquo;s Common Stock, par value $0.001 per share (the &ldquo;Common
Stock&rdquo;), issued and outstanding prior to the Effective Time shall, automatically and without any action on the part of the
respective holders thereof, be combined and converted into one (1) share of Common Stock, par value $0.001 per share, of the Corporation
(the &ldquo;Reverse Split&rdquo;). No fractional share shall be issued in connection with the foregoing combination of the shares
pursuant to the Reverse Split. The Corporation will pay in cash the fair value of such fractional shares, without interest and
as determined in good faith by the Board of Directors of the Corporation when those entitled to receive such fractional shares
are determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reverse Split shall occur automatically without any further action by the holders of Common Stock, and whether or not the certificates
representing such shares have been surrendered to the Corporation; provided, however, that the Corporation shall not be obligated
to issue certificates evidencing the shares of Common Stock issuable as a result of the Reverse Split unless the existing certificates
evidencing the applicable shares of stock prior to the Reverse Split are either delivered to the Corporation, or the holder notifies
the Corporation that such certificates have been lost, stolen or destroyed, and executes an agreement satisfactory to the Corporation
to indemnify the Corporation from any loss incurred by it in connection with such certificates.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The
foregoing amendments to the Certificate have been duly approved by the Corporation&rsquo;s Board of Directors in accordance with
Section 242 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. The
foregoing amendments to the Certificate have been duly approved by the Corporation&rsquo;s stockholders in accordance with Sections
211 and 242 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[SIGNATURE
PAGE TO CERTIFICATE OF AMENDMENT]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer on this
10th of August 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACTINIUM PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea125571ex99-1_actinium.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 10, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc. Announces Reverse Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK, NY &ndash; August 10, 2020 &ndash; <B>Actinium Pharmaceuticals, Inc.</B> (NYSE AMERICAN: ATNM) (&ldquo;Actinium&rdquo; or
the &ldquo;Company&rdquo;) today announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding
common stock that will become effective after trading closes on August 10, 2020. Trading of the Company common stock will begin
on a split-adjusted basis when markets open on August 11, 2020. The common stock will continue to trade on the NYSE American under
the ticker symbol &ldquo;ATNM,&rdquo; although a new CUSIP number 00507W206 has been assigned as a result of the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
effectiveness of the reverse stock split, every thirty (30) shares of the Company&rsquo;s pre-reverse split common stock will
be combined and reclassified into one (1) share of common stock. The reverse stock split will not modify any rights of the Company&rsquo;s
common stock. The reverse stock split will also apply to common stock issuable upon the exercise of the Company&rsquo;s outstanding
warrants and stock options, with a proportionate adjustment to the numbers of shares which can be purchased upon the exercise
of the warrants and stock options and the exercise prices thereof, and under the Company&rsquo;s equity incentive plan. Immediately
after the reverse stock split becomes effective, the Company will have approximately 13,585,268 shares of common stock outstanding
(subject to surrender of fractional shares in exchange for cash payment in lieu). No fractional shares will be issued following
the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, on December 18, 2019, the Company&rsquo;s stockholders approved &nbsp;a proposal authorizing the Company&rsquo;s
Board of Directors to effect a&nbsp;reverse&nbsp;stock split&nbsp;at its discretion at a ratio not greater than 1-for-75 in order
to help regain compliance with the NYSE American&rsquo;s minimum price requirements. The Board of Directors approved the reverse
stock split at a ratio of 1-for-30 on August 7, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of record will be receiving information regarding their share ownership following the reverse stock split from the Company&rsquo;s
transfer agent, Action Stock Transfer. Action Stock Transfer Corp can be reached at (801) 274-1088. Additional information about
the reverse stock split can be found in the Company&rsquo;s definitive proxy statement on Schedule 14A, filed with the U.S. Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) on November 25, 2019, and available free of charge at the SEC&rsquo;s website,
www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine
the targeting ability of antibodies with the cell killing ability of radiation. Actinium&rsquo;s lead application for our ARCs is targeted
conditioning, which is intended to selectively kill patient&rsquo;s cancer cells and certain immune cells prior to a BMT or Bone Marrow
Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities.
With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating
or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate,
Iomab-B is being studied in the ongoing pivotal Phase 3 <B>S</B>tudy of <B>I</B>omab-B in <B>E</B>lderly <B>R</B>elapsed or <B>R</B>efractory
<B>A</B>cute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising
single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Beyond Iomab-B, we
are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted
conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with
a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Underpinning
our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property
portfolio of over 120 patents, know-how, collective research and expertise in the field are being leveraged to construct and study
novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being
utilized in a collaborative research partnership with Astellas Pharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain projections or other &ldquo;forward-looking statements&rdquo; within the meaning of the &ldquo;safe-harbor&rdquo;
provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance
of the Company which the Company undertakes no obligation to update, including but not limited to, statements relating to the
Company&rsquo;s expectations regarding the intended use of proceeds of the public offering. These statements are based on management&rsquo;s
current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated
or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final
results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental
agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium&rsquo;s products
and services, performance of clinical research organizations and other risks detailed from time to time in Actinium&rsquo;s filings
with the SEC, including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q
and Forms 8-K, each as amended and supplemented from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hans
Vitzthum</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hans@LifeSciAdvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P:
(617) 535-7743</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "% B4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)CD;*LJ\8SUYJ]^U!^V]%^RG="37?!'B>[T6618+?5K22V-O<2E"Y0*THD!
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M_P $RM;NM;^!5E)=3RW#BWA&Z1MQ_P!6O>OI*2,2QE6&0PP1ZUYA^RO^S_\
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M=7JZ2]R'O+L_=VZON]=SD_U#R3V="E[)\M!WA^\J>ZULU[^Z6B>Z6BT/FO\
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MSQ7RW\4/^"E,WPEO;2[USX3>/=-\*WLXAAU:\1+=I<\Y$)Y!(R0KLK$ \5]
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M-MSUKW$Q1@4%MM<_\1?BIH/PG\'ZGK_B#4[72]'T:UDO;V[G?$=M#&I9W;V
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M:QDG*G/GBE[T5%Q:?O)JW;E?<W/A3*(/^"<6F.?X? ;'_P DVKR?_@BDN[X
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M*07E[X?T:WLI9>TCH@W$9[;LX]L5WW@O]F?PAX%U+[79:5 EQUW$9KOE4*,
M<#I7SV=\5U,;!4J4>6*_$^CP>3PIR]I5U8B1B-< 8 KE_C'\'=!^.OP^U'PU
MXCL(=1TO4XC%+%(/Q!!ZJP(!##D$ CFNJHKY)2:?,MSVK)JS/QZ_:9_8%G^'
M_B>[\(Z[&=0@N0[:1J3QX&IPCG8Q' N(Q][^]PP[@?-OP[\.>+/V+_C/8:QH
M]Q<6D]I-OMKA>!.@ZQN.G3@CO7[R_&WX+Z5\;?!DVEZBA5\B6VN$XEM95Y61
M&[,#_4'@U\1?&7]F./Q):ZAX?UVU1=<L5+[T78+V,<+<Q>A_O+_">.A%>Z\U
MJXB"ISUE^9YLL-3H7J;1/J;]C+]KG2?VIOAM;WD31V^L0($O;0GF)\<D?[)[
M&K?[7WP_O]?^!?BV7P^-GB'^Q[M=.8<%;@PN(B/??MK\K_A[XY\4_L9_&.&Z
MMI'1H'Y'(CO8L\@C^8[&OUA_9S_:%T+]ISX:PZE82(6D39=6S-EX7QRIK.6#
MQ>!4<7%:'GX?.<#F-26"YES+6W==T?RY>"_B;XG\->'[WP_-)<VC!C#?6TH(
MECF0D.K@\A@V<Y[U_0[_ ,$,-/\ $>B_\$U? %EXF%RMW ER]HEQGS(;-[B1
M[="#R (V&!V&!71>,O\ @E?\+_&?Q4F\63^'='_M2YD$D\[6:&29AW8X^8^Y
MR:^B?"GA>T\':'!86<8C@@4*H KUN(.)H9CAJ=",&FM6W^AV8#+'AZLJC=[F
ME1117QYZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 R:!9XRK<JPP1ZUROPH^!GA3X&Z-/8>%
M-%M-&M[J4SW!B!:2X<DG<[L2SGDXR3CM76T5I&K4C!TXR:B[75]';:ZZVZ&$
M\-1G4C6G%.4;V=M5?>SZ7ZV"BBBLS<**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "JFI:'::Q'MNK:&=1V=0<5;HH @L=.@TV$1V\
M,<*#H$7%3T44 %%%% !1110 5P_QK^#EO\4=#4QO]CU:Q;SK*[0?-#)C]5/1
ME/!!KN*1NE5&;A)2CNB*E.-2#IS5TS\[/VDO@E#X_P!!U2WU.S6PU_1U:2YC
MC'^K8 D31$]8VQ_,'D5X#_P32^+GCVV_:5TW2? 6C3:Z;C#ZM \_E6=M:9PT
MTTF"$ _AX+,V  :_4SX[?L]Z?\:?#]PBSG2=:-M+!:ZE'%YC0;U(.Y<C>A[J
M2.V"",U7_92_9.\)?L@?#"'PUX5M,;MLNH:A, ;O59P,&:9NY]%'RJ.  *_1
M(<9T(Y5*A*FI5):6:]VW?_+K?TU_#%X7YB^(UB57<<-!J<9)^_?^3_-NZ:Z7
MO;TR.G445^<G[L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
